National Network of Depression Centers' Recommendations on Harmonizing Clinical Documentation of Electroconvulsive Therapy.

Electroconvulsive therapy (ECT) is a highly therapeutic and cost-effective treatment for severe and/or treatment-resistant major depression. However, because of the varied clinical practices, there is a great deal of heterogeneity in how ECT is delivered and documented. This represents both an opportunity to study how differences in implementation influence clinical outcomes and a challenge for carrying out coordinated quality improvement and research efforts across multiple ECT centers. The National Network of Depression Centers, a consortium of 26+ US academic medical centers of excellence providing care for patients with mood disorders, formed a task group with the goals of promoting best clinical practices for the delivery of ECT and to facilitate large-scale, multisite quality improvement and research to advance more effective and safe use of this treatment modality. The National Network of Depression Centers Task Group on ECT set out to define best practices for harmonizing the clinical documentation of ECT across treatment centers to promote clinical interoperability and facilitate a nationwide collaboration that would enable multisite quality improvement and longitudinal research in real-world settings. This article reports on the work of this effort. It focuses on the use of ECT for major depressive disorder, which accounts for the majority of ECT referrals in most countries. However, most of the recommendations on clinical documentation proposed herein will be applicable to the use of ECT for any of its indications.

Informations de copyright

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

D.F.M. has received research support for the clinical study of ketamine in depression and past travel expenses for program and research development from the National Network of Depression Centers. He has research support from Janssen at present. He has past research funding from Neuronetics and St. Jude Medical in the past 10 years; Mustafa Husain has received support from the National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke, Brain Initiative, and the Stanley Medical Research Institute. He has received industry grant support from Abbott, Cyberonics, Neuronetics, Brainsway, and NeoSync; William M. McDonald is a member of the American Psychiatric Association Council on Research representing electroconvulsive therapy and neuromodulation therapies. He is compensated as the chair of the Data Safety and Monitoring Board (DSBM) for an NIA multicenter study. He is on the Board of Skyland Trail and 3Keys. He is a paid consultant for Signant Health. He has received past funding from the Stanley Foundation, Soterix, Neuronetics, NeoSync, and Cervel Neurotherapeutics. He has an endowed chair funded by the JB Fuqua Foundation. S. Selek received internal funding from the University of Texas Health Science Center at Houston McGovern Medical School, Louis A. Faillace Department of Psychiatry. S.M.M. has received research funding from the NIH and is a consultant for the Pearson Assessment. E.A. has received funding from the NIA. J.H.W. is a consultant or has equity interest at Mindstreet Inc; American Psychiatric Publishing, Inc; Guilford Press; and Simon and Schuster Book Royalties. He has received grant support from the Agency for Healthcare Research and Quality. T.S. has received funding from the NIH and the Foundation of Hope for Research and Treatment of Mental Illness. W.I. has received funding from the NIMH T32 Psychiatric Epidemiology Training Program (T32MH014592-41). I.M.R. was supported by the NIMH (R01 MH121542) and The Jager Family Foundation. P.P.Z., M.M., R.W.S., S.K.C., K.R., B.R.C., S.J.S., P.D.P., R.D.W., N.F.R., M.T.B., M.C., K.G., A.F., N.T.T., O.F.P., M.J.D., K.K., S. Sampson, and Y.S. have no conflicts of interest or financial disclosures to report.